BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Ebola outbreak
Hantavirus
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Saturday, June 20, 2026
Home
»
Newsletters
» BioWorld
BioWorld
April 21, 2010
View Archived Issues
ThromboGenics Stock Climbs on Microplasmin Phase III Data
Read More
Gemin X Adds $16M Ahead of SCLC Data, Partnering Talks
Read More
FDA's Negative Acurox Review Sends Acura Shares into a Slide
Read More
Biogen Earnings Miss the Mark on Charges, Lower Tysabri Sales
Read More
Gilead Stops Hepatitis C Program on Safety Issues
Read More
Clinic Roundup
Read More
Other News To Note
Read More
AACR Roundup
Read More
Array, Novartis Strike MEK Inhibitor Deal Worth up to $467M
Array BioPharma Inc. has snagged another oncology deal involving its MEK inhibitors, this time with Novartis AG in a collaboration that will bring in $45 million up front plus $422 million in milestones. (BioWorld Today)
Read More
Forest Axes Phenomix Diabetes Deal Despite Good Phase III Data
Read More
